Cargando…

The role of G-CSF neuroprotective effects in neonatal hypoxic-ischemic encephalopathy (HIE): current status

Hypoxic-ischemic encephalopathy (HIE) is an important cause of permanent damage to central nervous system (CNS) that may result in neonatal death or manifest later as mental retardation, epilepsy, cerebral palsy, or developmental delay. The primary cause of this condition is systemic hypoxemia and/o...

Descripción completa

Detalles Bibliográficos
Autores principales: Dumbuya, John Sieh, Chen, Lu, Wu, Jang-Yen, Wang, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897393/
https://www.ncbi.nlm.nih.gov/pubmed/33612099
http://dx.doi.org/10.1186/s12974-021-02084-4
_version_ 1783653661586489344
author Dumbuya, John Sieh
Chen, Lu
Wu, Jang-Yen
Wang, Bin
author_facet Dumbuya, John Sieh
Chen, Lu
Wu, Jang-Yen
Wang, Bin
author_sort Dumbuya, John Sieh
collection PubMed
description Hypoxic-ischemic encephalopathy (HIE) is an important cause of permanent damage to central nervous system (CNS) that may result in neonatal death or manifest later as mental retardation, epilepsy, cerebral palsy, or developmental delay. The primary cause of this condition is systemic hypoxemia and/or reduced cerebral blood flow with long-lasting neurological disabilities and neurodevelopmental impairment in neonates. About 20 to 25% of infants with HIE die in the neonatal period, and 25-30% of survivors are left with permanent neurodevelopmental abnormalities. The mechanisms of hypoxia-ischemia (HI) include activation and/or stimulation of myriad of cascades such as increased excitotoxicity, oxidative stress, N-methyl-d-aspartic acid (NMDA) receptor hyperexcitability, mitochondrial collapse, inflammation, cell swelling, impaired maturation, and loss of trophic support. Different therapeutic modalities have been implicated in managing neonatal HIE, though translation of most of these regimens into clinical practices is still limited. Therapeutic hypothermia, for instance, is the most widely used standard treatment in neonates with HIE as studies have shown that it can inhibit many steps in the excito-oxidative cascade including secondary energy failure, increases in brain lactic acid, glutamate, and nitric oxide concentration. Granulocyte-colony stimulating factor (G-CSF) is a glycoprotein that has been implicated in stimulation of cell survival, proliferation, and function of neutrophil precursors and mature neutrophils. Extensive studies both in vivo and ex vivo have shown the neuroprotective effect of G-CSF in neurodegenerative diseases and neonatal brain damage via inhibition of apoptosis and inflammation. Yet, there are still few experimentation models of neonatal HIE and G-CSF’s effectiveness, and extrapolation of adult stroke models is challenging because of the evolving brain. Here, we review current studies and/or researches of G-CSF’s crucial role in regulating these cytokines and apoptotic mediators triggered following neonatal brain injury, as well as driving neurogenesis and angiogenesis post-HI insults.
format Online
Article
Text
id pubmed-7897393
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78973932021-02-22 The role of G-CSF neuroprotective effects in neonatal hypoxic-ischemic encephalopathy (HIE): current status Dumbuya, John Sieh Chen, Lu Wu, Jang-Yen Wang, Bin J Neuroinflammation Review Hypoxic-ischemic encephalopathy (HIE) is an important cause of permanent damage to central nervous system (CNS) that may result in neonatal death or manifest later as mental retardation, epilepsy, cerebral palsy, or developmental delay. The primary cause of this condition is systemic hypoxemia and/or reduced cerebral blood flow with long-lasting neurological disabilities and neurodevelopmental impairment in neonates. About 20 to 25% of infants with HIE die in the neonatal period, and 25-30% of survivors are left with permanent neurodevelopmental abnormalities. The mechanisms of hypoxia-ischemia (HI) include activation and/or stimulation of myriad of cascades such as increased excitotoxicity, oxidative stress, N-methyl-d-aspartic acid (NMDA) receptor hyperexcitability, mitochondrial collapse, inflammation, cell swelling, impaired maturation, and loss of trophic support. Different therapeutic modalities have been implicated in managing neonatal HIE, though translation of most of these regimens into clinical practices is still limited. Therapeutic hypothermia, for instance, is the most widely used standard treatment in neonates with HIE as studies have shown that it can inhibit many steps in the excito-oxidative cascade including secondary energy failure, increases in brain lactic acid, glutamate, and nitric oxide concentration. Granulocyte-colony stimulating factor (G-CSF) is a glycoprotein that has been implicated in stimulation of cell survival, proliferation, and function of neutrophil precursors and mature neutrophils. Extensive studies both in vivo and ex vivo have shown the neuroprotective effect of G-CSF in neurodegenerative diseases and neonatal brain damage via inhibition of apoptosis and inflammation. Yet, there are still few experimentation models of neonatal HIE and G-CSF’s effectiveness, and extrapolation of adult stroke models is challenging because of the evolving brain. Here, we review current studies and/or researches of G-CSF’s crucial role in regulating these cytokines and apoptotic mediators triggered following neonatal brain injury, as well as driving neurogenesis and angiogenesis post-HI insults. BioMed Central 2021-02-21 /pmc/articles/PMC7897393/ /pubmed/33612099 http://dx.doi.org/10.1186/s12974-021-02084-4 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Dumbuya, John Sieh
Chen, Lu
Wu, Jang-Yen
Wang, Bin
The role of G-CSF neuroprotective effects in neonatal hypoxic-ischemic encephalopathy (HIE): current status
title The role of G-CSF neuroprotective effects in neonatal hypoxic-ischemic encephalopathy (HIE): current status
title_full The role of G-CSF neuroprotective effects in neonatal hypoxic-ischemic encephalopathy (HIE): current status
title_fullStr The role of G-CSF neuroprotective effects in neonatal hypoxic-ischemic encephalopathy (HIE): current status
title_full_unstemmed The role of G-CSF neuroprotective effects in neonatal hypoxic-ischemic encephalopathy (HIE): current status
title_short The role of G-CSF neuroprotective effects in neonatal hypoxic-ischemic encephalopathy (HIE): current status
title_sort role of g-csf neuroprotective effects in neonatal hypoxic-ischemic encephalopathy (hie): current status
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897393/
https://www.ncbi.nlm.nih.gov/pubmed/33612099
http://dx.doi.org/10.1186/s12974-021-02084-4
work_keys_str_mv AT dumbuyajohnsieh theroleofgcsfneuroprotectiveeffectsinneonatalhypoxicischemicencephalopathyhiecurrentstatus
AT chenlu theroleofgcsfneuroprotectiveeffectsinneonatalhypoxicischemicencephalopathyhiecurrentstatus
AT wujangyen theroleofgcsfneuroprotectiveeffectsinneonatalhypoxicischemicencephalopathyhiecurrentstatus
AT wangbin theroleofgcsfneuroprotectiveeffectsinneonatalhypoxicischemicencephalopathyhiecurrentstatus
AT dumbuyajohnsieh roleofgcsfneuroprotectiveeffectsinneonatalhypoxicischemicencephalopathyhiecurrentstatus
AT chenlu roleofgcsfneuroprotectiveeffectsinneonatalhypoxicischemicencephalopathyhiecurrentstatus
AT wujangyen roleofgcsfneuroprotectiveeffectsinneonatalhypoxicischemicencephalopathyhiecurrentstatus
AT wangbin roleofgcsfneuroprotectiveeffectsinneonatalhypoxicischemicencephalopathyhiecurrentstatus